Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113919 · ClinicalTrials.gov registry record · Phase 1
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
A Phase 1 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00113919 is a Phase 1 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 14 participants.
The verdict
NCT00113919, a Phase 1 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if patients with high risk disease because of age or kidney status can be treated more safely with a drug called Busulfex® followed by autologous transplant compared to treatment with the standard drug called melphalan, which has been shown to be quite difficult to tolerate in patients with poor kidney function and patients over the age of 65 when given in high doses.
Interventions
- DRUG Busulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113919
The ClinicalTrials.gov registry entry for NCT00113919 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Busulfan is the first listed.
NCT00113919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113919 about?
NCT00113919 is a clinical study titled "UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients". The purpose of this study is to find out if patients with high risk disease because of age or kidney status can be treated more safely with a drug called Busulfex® followed by autologous transplant compared to treatment with the standard drug called melphalan, which has been shown to be quite diffic...
What is the current status of trial NCT00113919?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2004-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00113919?
The interventions under investigation include: Busulfan (DRUG).
Who is sponsoring clinical trial NCT00113919?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.